NCT03812809View on ClinicalTrials.gov

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

January 24, 2022

Study Completion Date

January 24, 2022

Conditions
NSCLC
Interventions
DRUG

BPI-7711

BPI-7711: 180mg, QD, oral

Trial Locations (3)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Unknown

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Linyi Cancer Hospital, Linyi

Sponsors
All Listed Sponsors
lead

Beta Pharma Shanghai

INDUSTRY

NCT03812809 - A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive | Biotech Hunter | Biotech Hunter